Home / Cancer treatment in China / Colorectal cancer treatment
Decision map
Colorectal Cancer Treatment
Colorectal cancer treatment depends on the primary site, stage, resectability, metastatic sites, prior treatment, and markers such as RAS, BRAF, MSI or MMR, and HER2 when it is relevant. Surgery is the common curative route for many localized colon and rectal cancers. Chemotherapy, radiation, targeted drugs, and immunotherapy are added only when those factors support them. No single stage or single marker is a prescription. This page routes the question. It does not assign a plan.
Applicability: colon and rectal cancers share a name and do not share one sequence. A biomarker without the stage is not a plan.
Colon is not rectumStage is not the only switchNot a personal plan
What the plan actually uses
The same five facts come before a drug name: colon or rectum, stage, whether the disease can be removed, where any metastases are, and prior treatment. The markers that change drug choice are RAS and NRAS, BRAF, MSI or MMR, and HER2 when that test was done. Other actionable findings are read the same way. Patient fitness still matters. One of those facts is not a plan.
The most common curative tool for a localized tumor is surgery. Chemotherapy is added when risk or spread justifies it. Radiation is much more often part of rectal treatment than of colon treatment. Targeted drugs and immunotherapy wait for the matching marker. The stage page, the metastatic page, and the immunotherapy page split those questions.
What this is not
It is not a China hospital advertisement and it is not a drug catalogue. China-specific labels and access sit on colorectal cancer treatment in China. The 2026 evidence table sits on new colorectal cancer treatments in 2026.
When a case review may help
A review can sort which records a hospital would need: pathology, colon or rectum, imaging, prior regimens, and the marker report. It does not assign a stage or hold a bed.
In this cluster
- Colorectal cancer treatment (this page)
- Treatment by stage
- Metastatic disease
- Immunotherapy
- New treatments in 2026
- Treatment in China
Technology pages already on this site, used only when a case actually needs them: proton therapy, microwave ablation, cryoablation, and interventional oncology. None of those replaces surgery or systemic therapy for colorectal cancer as a default.
Questions people ask
What is the most common treatment for colorectal cancer?
For many localized tumors, surgery is the common curative treatment. Chemotherapy, radiation, targeted therapy, and immunotherapy are added only when site, stage, resectability, prior treatment, and biomarkers support them. There is no single regimen for every colorectal cancer.
Can colorectal cancer be cured?
Some localized colorectal cancers are treated with curative intent, usually with surgery, and do not return. That is not a guarantee. Metastatic disease is a different question. A response, a period off treatment, and a cure are not the same result.
What biomarkers matter in colorectal cancer?
RAS and NRAS, BRAF, MSI or MMR, and HER2 when it is relevant. Other actionable findings are read the same way. A marker changes drug choice. It does not replace stage, resectability, or prior treatment.
Sources
- NCI, Colon Cancer Treatment (PDQ) patient version. Used for the general distinction between colon treatment and a personal plan.
- NCI, Rectal Cancer Treatment (PDQ) patient version. Used for the point that rectal cancer more often involves radiation than colon cancer.
- National Health Commission colorectal cancer specification, 2025 edition. English summary: Chin J Cancer Res 2025;37(6):949-961. doi 10.21147/j.issn.1000-9604.2025.06.07. This is a practice framework, not a 2026 drug list.
- CSCO colorectal guideline version 2026, as interpreted in Chin J Cancer Res 2026;38(3):329-335. doi 10.21147/j.issn.1000-9604.2026.03.10. The full guideline PDF was not pasted here.
- Cao and Jiang, 1 October 2026. Digestive Oncology, electronic edition, 2026;18(3):358-363. Used for the metastatic nivolumab sentence, the stage III dMMR adjuvant sentence, and the first-line BRAF move.
Last reviewed: 3 October 2026. A trial permission, a guideline sentence, and a drug label are three different documents.
Check whether this treatment route fits my case
This is a records question, not a treatment assignment. ParkMega does not choose a drug, reserve a bed, or promise a response.